Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial.
Haipeng Zhang, Wei Song, Jinliang Ni et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, single-blind, sham-controlled trial evaluated the P100 extracorporeal shock wave therapy device in 83 patients with type IIIB chronic prostatitis/chronic pelvic pain syndrome. Participants received four weekly low-intensity treatment sessions or sham procedures. At week 4, 78.4% of the P100 group met the clinical response threshold, compared with 25% of controls (P < 0.001). NIH-CPSI scores also fell from a median of 35 at baseline to 13 at week 4 and 12 at week 8, with symptom improvement reported as sustained through week 8.
Key findings
- At week 4, clinical response rates were 78.4% with P100 and 25% with sham (P < 0.001).
- Median NIH-CPSI scores decreased from 35 at baseline to 13 at week 4 and 12 at week 8.
- PDS, IPSS, and VAS scores showed significant reductions by week 2 (P < 0.05), with relief stable through week 8.
- No treatment-related adverse events were reported.
Why it matters
The sham-controlled comparison suggests that P100 ESWT may provide short-term symptom relief beyond the procedure’s nonspecific effects in type IIIB CP/CPPS. Improvement across pain and urinary measures, alongside the reported absence of treatment-related adverse events, makes the approach clinically relevant for further evaluation. The findings remain preliminary regarding durability and erectile-function outcomes.
What to keep in mind
Follow-up was limited to week 8, and the authors call for larger studies with longer-term follow-up. The trial was single-blind.